The Ridgewood Blog Brings a Free Market Laissez-faire Point of View to Local, New Jersey State and National Issues.
the staff of the Ridgewood blog
Ridgewood NJ, the COVID19 vaccine developed by Pfizer appears to be effective against the more transmissible variants of the coronavirus, including the one first discovered in South Africa, according to a new report in the New England Journal of Medicine.
Continue reading Pfizer Vaccine Protects Against U.K., South Africa Variants of Coronavirus
the staff of the Ridgewood blog
Hackensack NJ, Hackensack Meridian Health, the largest and most integrated health network in New Jersey, has administered COVID-19 vaccinations to more than 13,000 frontline team members and physicians and is now opening scheduling to additional team members and physicians. The move is designed to increase voluntary participation and ensure that the maximum number of team members are vaccinated as quickly as possible.
the staff of the Ridgewood blog
CAMBRIDGE, Mass. Moderna, Inc., (Nasdaq:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today confirmed that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended that the FDA grant an Emergency Use Authorization (EUA) for the Company’s COVID-19 vaccine candidate, mRNA-1273. 20 VRBPAC members recommended for EUA, 0 members voted against, and 1 abstained.
the staff of the Ridgewood blog
CAMBRIDGE, Mass., Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the independent, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, has informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%. This study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.
Continue reading Moderna’s COVID-19 Vaccine 94.5% Effective !